The Dresner Foundation in West Bloomfield, Michigan, has announced three grants totaling more than $1 million for myelodysplastic syndrome research.
Myelodysplastic syndromes are a group of bone marrow disorders in which the bone marrow does not produce enough healthy blood cells. Although MDS is primarily a disease of those over the age of 65, it can affect younger people as well.
Awarded through the Dresner Foundation's new Myelodysplastic Syndrome Research Fund, the grants will support two early-career investigators and one established career investigator pursuing cutting-edge MDS research and related programs that could lead to advances in the future standard of care and, ultimately, a cure. Grant recipients include Stephen Chung (Memorial Sloan Kettering), who will examine the effectiveness of bone marrow transplantation, the only known cure for MDS; Coleman Lindsley (Dana-Farber Cancer Institute), who will study the reasons why different mutations cooperate to cause MDS with the goal of creating a more reliable method to identify youth most at risk for developing MDS; and Gregory Abel (Dana Farber), who is studying how to tailor transfusion decisions to the quality-of-life changes experienced by individual patients.
"Joseph Dresner's struggle with MDS motivated him to help physician researchers find a cure for this disease, and improve the quality of life of others with MDS," said Mikkael A. Sekeres, chair of the MDS Research Fund scientific advisory board. "My father would be pleased to see that his legacy is helping to fund the best that investigative MDS research scientists and medical institutions have to offer."
(Photo credit: Dana-Farber Cancer Institute)